Antibe Therapeutics Announces Amendment to Warrant Terms
15 Juin 2022 - 01:00PM
Business Wire
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the
"Company"), a clinical stage company leveraging its hydrogen
sulfide platform to develop next-generation safer therapies that
target inflammation, announces that it is extending the expiry date
(the “Warrant Extension”) and amending the exercise price
(the “Amended Exercise Price”) of 3,117,957 common share
purchase warrants (“Warrants”) of the Company.
Warrant Extension and
Amendment
The Warrants, pursuant to the Warrant Extension, will expire on
December 31, 2023 and, pursuant to the Amended Exercise Price, be
exercisable into a common share of the Company at $1.80 per common
share, as depicted in the table below:
Issue Date
Number of Warrants
Issued Exercise Price
Amended Exercise Price
Original Expiry Date
Amended Expiry Date
Effective Date
June 30, 2020
2,373,401
$6.00
$1.80
June 30, 2022
December 31, 2023
June 30, 2022
August 13, 2019
744,556
$4.00
$1.80
August 13, 2022
December 31, 2023
June 30, 2022
None of the Warrants are held by insiders of the Company.
The Toronto Stock Exchange has provided conditional approval for
the Warrant Extension and Amended Exercise Price with an effective
date for the amendments of June 30, 2022.
About Antibe Therapeutics Inc. Antibe is a clinical stage
biotechnology company leveraging its proprietary hydrogen sulfide
platform to develop next-generation safer therapies that target
inflammation arising from a wide range of medical conditions. The
company’s current pipeline includes assets that seek to overcome
the gastrointestinal (“GI”) ulcers and bleeding associated with
nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead
drug, otenaproxesul, is in clinical development as a safer
alternative to opioids and today’s NSAIDs for post-operative pain.
Antibe’s second pipeline drug, ATB-352, is being developed for a
specialized acute pain indication. The company’s anticipated next
target is inflammatory bowel disease (“IBD”), a condition long in
need of safer, more effective therapies. Learn more at
antibethera.com.
Forward-Looking Statements This press release contains
forward-looking statements identified by words such as “expects”,
“will” and similar expressions, which reflect the Company’s current
expectations regarding future events. The forward-looking
statements involve risks and uncertainties that could cause the
Company’s actual events to differ materially from those projected
herein. Investors should consult the Company’s ongoing quarterly
filings and annual reports for additional information on risks and
uncertainties relating to these forward-looking statements. The
reader is cautioned not to rely on these forward-looking
statements. The Company disclaims any obligation to update these
forward-looking statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220615005402/en/
Antibe Therapeutics Inc. Christina Cameron VP Investor
Relations +1 416-577-1443 christina@antibethera.com
Antibe Therapeutics (TSX:ATE)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Antibe Therapeutics (TSX:ATE)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024